Page 13 - Urovant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA (vibegron), in the Journal of Urology Urovant Sciences, a wholly owned subsidiary of Sumitovant, announced today that the Journal of Urology has published positive safety and efficacy data from the GEMTESA (vibegron) double-blind 40-week extension study with patient data over a total exposure of 52 weeks (NCT03583372) in the print version of the Journal of Urology. The peer-reviewed publication is currently available online and the print arti...

The American Urological Association and Urology Care Foundation Unveil New Urology Research Program Supported by $2 Million Donation from Urovant Sciences New Research Program Focuses on Supporting Young Scientists Underrepresented in the Field of Urology News provided by Share this article Share this article BALTIMORE, April 1, 2021 /PRNewswire/ -- The American Urological Association (AUA) and Urology Care Foundation today announced the launch of a program aimed at fostering diversity and inclusion in urology research, supported by a generous $2 million donation from Urovant Sciences (Urova...

Altasciences Performs Phase I Studies for FDA Approval of Vibegron Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials. Vibegron is a beta-3 adrenergic receptor (ß3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. The approval was announced by Urovant Sciences on December 23, 2020. " We take tremendous pride in contributing to the FDA approval of much-needed medicines that improve the health and wellbeing of pat...

(MENAFN - GetNews) DelveInsight's "Urinary Incontinence Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Urinary Incontinence, historical and forecasted epidemiology as well as the Urinary Incontinence market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Urinary incontinence , which is also known as the loss of bladder control is a common problem in which a person leaks urine by chance. Although, it may happen to anyone but older people especially women are severely affected by this ...

Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids •LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline •Achieved six of seven key secondary endpoints including reduction of pain •Bone mineral density maintained at levels comparable to placebo •Data were included in U.S. New Drug Application for relugolix combination tablet for ut...